Peripheral blood immunophenotypic diversity in patients with rheumatoid arthritis and its impact on therapeutic responsiveness
Authors' conclusion
Our findings offer valuable insights into the diversity of RA and potential therapeutic strategies grounded in the molecular underpinnings.
Study context
- Population
- b/tsDMARD-naïve patients with rheumatoid arthritis (RA), stratified by peripheral blood immunophenotypeover 500
- Exposure
- Expected vs non-expected
- Outcome
- Remission
- Follow-up
- 26 weeks
Methodological detailsflow cytometry immunophenotyping, validation cohort
- Flow cytometry immunophenotyping
- Validation cohort
Main finding
As reported in the abstract
P = 0.0004
Observational data: associations, not effects.
Further findings
Low disease activity achievement · 26 weeks
P < 0.0001
- Remission, validation cohort · higher remission rate in expected group
- P = 0.0021
- Remission, validation cohort: 183 cases
26-week disease activity (trajectory analysis)
- Influenced by baseline CDAI in non-expected group, unlike expected group
Original publication
Peripheral blood immunophenotypic diversity in patients with rheumatoid arthritis and its impact on therapeutic responsiveness. Ann Rheum Dis. Published 2 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →